Reviewing Equillium (NASDAQ:EQ) and Prime Medicine (NASDAQ:PRME)

Equillium (NASDAQ:EQ) and Prime Medicine (NASDAQ:PRME) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Equillium and Prime Medicine, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1	1	7	2	2.91
Prime Medicine	1	0	7	1	2.89

Equillium currently has a consensus price target of $7.57, indicating a potential upside of 421.45%. Prime Medicine has a consensus price target of $7.86, indicating a potential upside of 105.85%. Given Equillium’s stronger consensus rating and higher probable upside, research analysts clearly believe Equillium is more favorable than Prime Medicine.

Valuation and Earnings

This table compares Equillium and Prime Medicine”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10 million	2.24	-$22.40 million	($0.20)	-7.26
Prime Medicine	$4.63 million	149.53	-$201.14 million	($1.06)	-3.60

Equillium has higher revenue and earnings than Prime Medicine. Equillium is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Equillium and Prime Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

Institutional and Insider Ownership

27.1% of Equillium shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 17.8% of Equillium shares are held by insiders. Comparatively, 16.0% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Equillium has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500.

Summary

Equillium beats Prime Medicine on 10 of the 14 factors compared between the two stocks.

About Equillium

Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company seeks to address immune-system dysregulation by developing treatments that selectively modulate immune-cell activity rather than broadly suppressing the immune system. Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, a protein involved in the activation and trafficking of certain T cells. The company has evaluated itolizumab in conditions including acute graft-versus-host disease and lupus nephritis.

About Prime Medicine

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.